Physician profile
Jerry Schwartz
NPI 1881721702
$4,966.07
in general payments reported to CMS, 2019-2025
38 companies · $863 in 2025
The $863 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $602 · 2021: $421 · 2022: $770 · 2023: $746 · 2024: $1,080 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,689.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $920.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $798.94 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $398.66 | 2020-2023 | Vraylar, Ubrelvy, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $377.89 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $341.37 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.69 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $303.32 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $245.17 | 2020-2025 | |
| Arbor Pharmaceuticals, INC. | $241.88 | 2019-2021 | |
| Edwards Lifesciences Corporation | $131.01 | 2025 | |
| Upsher-Smith Laboratories LLC | $109.90 | 2019-2022 | |
| Allergan, INC. | $91.74 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $81.37 | 2019-2023 | Xarelto |
| Idorsia Pharmaceuticals US INC | $44.30 | 2023-2024 | Quviviq |
| Acist Medical Systems, INC. | $44.00 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.